Vimarsana
Biggest News Aggregation in the World

Immune Tolerance Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immune Tolerance Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immune Tolerance Network Today - Breaking & Trending Today

Early peanut consumption slashes allergy risk by 71%, landmark study finds - Vimarsana News

Early peanut consumption slashes allergy risk by 71%, landmark study finds

A recent study published in NEJM Evidence found that feeding children peanut products regularly from infancy to age five reduced the rate of peanut allergy in adolescence by 71%, providing long-term prevention through early allergen consumption

Introducing peanut in infancy prevents peanut allergy into adolescence - Vimarsana News

Introducing peanut in infancy prevents peanut allergy into adolescence

NIH study finds protection lasts no matter how often kids eat peanut in later childhood.

Source: nih.gov
A Pioneer in Immunology | Rutgers University Foundation - Vimarsana News

A Pioneer in Immunology | Rutgers University Foundation

The work of Jeffrey Bluestone, who will be inducted into the Rutgers University Hall of Distinguished Alumni, has led to new treatments for cancer and autoimmune diseases.

Epicutaneous Immunotherapy in Children Aged 1 to 3 Effective for Peanut Allergy Desensitization - Vimarsana News

Epicutaneous Immunotherapy in Children Aged 1 to 3 Effective for Peanut Allergy Desensitization

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

Zura Bio Announces Appointment of Chief Scientific Officer - Vimarsana News

Zura Bio Announces Appointment of Chief Scientific Officer

14.04.2023 - Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role ... Seite 1